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The Saccharomyces cerevisiae proteins Tel1p and Mec1p are in-
volved in telomere length regulation and cellular responses to DNA
damage. The closest relative of these proteins is the human Ataxia
Telangiectasia Mutated (ATM) protein, a wortmannin-sensitive
protein kinase that primarily phosphorylates serines in an SQ
motif. We constructed yeast strains containing functional epitope-
tagged versions of Tel1p and Mec1p. We showed that immuno-
precipitated Tel1p and Mec1p were capable of in vitro phosphor-
ylation of the mammalian protein PHAS-I (Phosphorylated Heat
and Acid Stable protein). These activities are sensitive to wort-
mannin. Tel1p phosphorylates serine in an SQ motif in PHAS-I.
Mutations in the kinase domains of Tel1p and Mec1p result in loss
of in vitro kinase activity and the in vivo phenotypes associated
with the null tel1 and mec1 mutations.
The Saccharomyces cerevisiae Tel1 and Mec1 proteins regulatetelomere length (1–3) and cellular responses to DNA dam-
age (4–8). Strains with the tel1 mutation have very short, but
stable, telomeres (1). Although strains with the mec1 mutation
have telomeres that are only slightly shorter than wild type,
strains with both tel1 and mec1 mutations have very short
telomeres and a senescent phenotype (3). Genetic studies dem-
onstrate that Tel1p is in the same pathway of telomere length-
regulation as the Mre11, Rad50, and Xrs2 proteins (9), whereas
Mec1p is in a different pathway (3).
Strains with the mec1 mutation are sensitive to DNA-
damaging agents (such as x-rays, UV light, and methylmethane
sulfonate) and agents that lead to S phase arrest (hydroxyurea;
refs. 4–8). Although tel1 cells are not sensitive to DNA-
damaging agents or hydroxyurea, one extra copy of TEL1 can
compensate for much of the damage sensitivity of mec1 strains
(7, 8). These results suggest that Tel1p and Mec1p have func-
tionally redundant roles in the repair of certain types of DNA
damage. In addition to its role in DNA repair and telomere
regulation, Mec1p has an essential cellular function, because null
mec1 mutants are inviable (4, 5). This lethality can be suppressed
by genetic alterations (such as a mutation in the SML1 gene) that
elevate nucleotide pools (10).
Mec1p is a checkpoint protein, because strains with a mutation
in mec1 fail to arrest the cell cycle in response to DNA damage
or the inhibition of DNA synthesis (4, 11). In response to DNA
damage or S phase arrest, Mec1p-dependent phosphorylation is
observed for a number of checkpointyDNA replication proteins
such as Rad53p (8, 11). In the absence of Mec1p, Te11p-
dependent phosphorylation is observed for several of these
proteins (8). These results suggest, but do not prove, that Tel1p
and Mec1p are protein kinases with the ability to phosphorylate
similar substrates.
Tel1p and Mec1p are related structurally to a variety of
mammalian proteins involved in DNA repair, maintenance of
genomic stability, and telomere length regulation. Tel1p and
Mec1p have a C-terminal domain of approximately 400 amino
acids that is shared with a number of protein kinases including
the mammalian proteins ATM, ATR, DNA-PK, and mTOR, and
the yeast protein kinases Rad3 (Schizosaccharomyces pombe)
and Tor1p (S. cerevisiae) (2, 7, 12). Although the C-terminal
domain has sequence similarities to domains observed in phos-
phatidylinositol-3 kinases (13), all of the kinases described above
phosphorylate proteins rather than lipids. Several of the mam-
malian kinases have overlapping substrate specificity; p53 is
phosphorylated by both ATR (14) and DNA-PK (15) in addition
to ATM (16). These same three kinases also are capable of
phosphorylating the mammalian translation repressor, PHAS-I
(Phosphorylated Heat and Acid Stable protein) (16, 17).
The sites phosphorylated by ATM and related mammalian
proteins have been mapped for a number of their substrates.
Many of these sites represent phosphorylation of serine or
threonine followed by a glutamine (18). In addition, ATM
(16, 17), DNA-PK (17), ATR (17), and Tor1p (19) are inhib-
ited by wortmannin, a fungal metabolite that covalently modi-
fies a lysine within the kinase domain of phosphoinositide
3-kinases (20).
The structural similarity of Tel1p and Mec1p with the ATM
family of kinases also is ref lected in similar cellular roles. For
example, as observed with yeast mec1 cells, human AT cells are
sensitive to DNA-damaging agents and have a defect in the
checkpoint response (11, 21). In addition, AT cells, as ob-
served with yeast tel1 cells, have chromosomes with short
telomeres (21).
Based on the observations described above, it is assumed that
Tel1p and Mec1p are protein kinases. In the experiments
described in Results, we directly demonstrate that both Tel1p and
Mec1p are wortmannin-sensitive protein kinases capable of in
vitro phosphorylation of PHAS-I. In an independent study,
Paciotti et al. (22) demonstrated recently that Mec1p phosphor-
ylated the yeast checkpoint protein Ddc2p in vitro and in vivo.
Materials and Methods
Plasmid and Strain Constructions. The genotypes of the yeast
strains used in our study are shown in Table 1. These strains
are isogenic with W303a (23, 24). We used the PCR epitope-
tagging procedure developed by Schneider et al. (25) to
prepare a yeast strain (KRY22) encoding a functional Tel1p
with a hemagglutinin (HA) epitope. The plasmid pMPY-
3xHA contains a URA3 gene f lanked by 3xHA repeats.
We PCR-amplified these sequences by using the primers TEL1
12,339 HA forward (59- CTCAAACAGGAACTTCTGCC-
ATCAATTACTTCGAAGCCTCTTCAGAAGACACTAC-
CAGGGAACAAAAGCTGG-39) and TEL1 12,448 HA re-
verse (59-GGAGTGCAGAGGCTTCTGAAATCTACCTCC-
Abbreviations: PHAS-1, phosphorylated heat and acid stable protein; HA, hemagglutinin.
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A AT TGTGTACGGACTAT TAT TCTGCTGTAGGGC-
GAATTGGG-39). The underlined segments are homologous
to the pMPY-3xHA, and the remainder of the primers repre-
sent TEL1 sequences. These primers were designed to insert
the 3xHA-URA3-3xHA sequences between amino acids 798
and 799 of Tel1p. The resulting DNA fragment was trans-
formed into W303a, and Ura1 transformants were purified.
Because the URA3 gene is f lanked by duplicated 3xHA epitope
sequences, recombination between these duplications results
in Ura2 derivatives that retain one copy of the 3xHA epitope.
We selected for such recombinants by using 5-f luoro-orotate.
By Southern analysis, we showed that strains with the HA-
tagged allele of TEL1 (TEL1-HA) had telomeres that were
elongated relative to those in tel1 strains but slightly shorter
('50 bp) than those in wild-type strains. In other strains, Tel1p
was epitope-tagged after amino acids 2 or 2,787, resulting in
functional and nonfunctional Tel1 proteins, respectively (data
not shown).
Strains with plasmid-borne TEL1 genes also were used in our
study. We previously constructed plasmids with the wild-type
TEL1 gene or a tel1 gene with four mutant substitutions in the
kinase domain (2). The plasmid pSP21 has the wild-type TEL1
gene inserted as a KpnI fragment into the SmaI site of the ADE3-
and URA3-containing high-copy-number vector pTSV31A (2).
The plasmid pSP-KD is identical to pSP21 except that the TEL1
gene has four mutant substitutions in the kinase domain (G–D
at position 2,611, D–A at position 2,612, N–K at position 2,616,
and D–E at position 2,631). Strains with pSP-KD have short
telomeres. To prepare a plasmid-borne HA-tagged TEL1 gene,
we transformed NheI- and BsiWI-treated pSP21 into the strain
with the HA-tagged chromosomal copy of TEL1 (KRY22). The
resulting gap-repair event resulted in a plasmid (pKR5) with a
plasmid-borne HA-tagged TEL1 gene; Southern analysis indi-
cated that this plasmid complemented the short-telomere
phenotype of tel1 strains, indicating that the plasmid-borne
TEL1-HA gene was functional.
We also constructed a plasmid with an HA-tagged TEL1 gene
with mutations in the kinase domain. The plasmid pKR5 was
treated with NheI and religated to delete an NheI fragment
containing the kinase domain and DNA sequences downstream
of TEL1 (pJM7). A 1.4-kb DNA fragment that included the NheI
sites and the kinase region was PCR-amplified from pSK-KD by
using the primers TEL1 17,400 forward (59-GTAATGAC-
GATTTGAGACAAGATGCAATTATGG-39) and TEL1
18,841 reverse (59-CGATAACAGAGCTAGCTTTATTC-
CATTAGACAACTT-39). This DNA fragment was treated with
NheI and inserted into the NheI site of pJM7 to generate the
plasmid pJM8, which contains the tel1-HA(KD) allele of TEL1.
Similar methods were used to construct a yeast strain (MD78)
encoding an HA-tagged Mec1p. The primers used to PCR-
amplify pMPY-3xHA sequences were MEC1 12,161 HA for-
ward (59-CTCGATATTTTCCAGAGATATATCATCCCTT-
ATGCAATTATTCAATATAGGGAACAAAAGCTGGAG-
CTC-39) and MEC1 12,259 HA reverse (59-TGTATCGCCA-
TCACACATAATCTTAGCAATTTCACTTAGCACATCG-
CTCTTCTGTAGGGCGAATTGGGTACC-39). These primers
are designed to insert the epitope between amino acids 736 and
737 of Mec1p. The PCR-generated DNA fragment was used to
Table 1. Strain names, strain constructions, and relevant genotypes
Strain name Strain construction or reference Relevant genotype*
W303a Ref. 23 Wild-type
W1588-4c Provided by R. Rothstein RAD5
JMY48 Transformation of W303a with plasmid pKR5 Wild-type, plasmid-borne TEL1-HA
JMY73 Ref. 3 sml1<HIS3
KRY22 Transformation of W303a with PCR fragment to introduce HA tag into TEL1† TEL1-HA
MD78 Transformation of JMY73 with PCR fragment to introduce HA tag into MEC1† sml1<HIS3 MEC1-HA
MD85 Two-step transplacement of MD78 with pMD81† sml1<HIS3 mec1-HA(KD)
JMY300-1a Ref. 3 a tel1<ura3 mec1-21
RCY278-5b Provided by R. Craven a RAD5‡
JMY303 Ref. 3 aya tel1<ura3yTEL1 mec1-21yMEC1
sml1<HIS3/SML1
JMY303-2a Spore of JMY303 tel1<ura3
KRY20a Ref. 3 ura3D<HIS3 tel1<ura3 ade3
JMY103 Transformation of KRY20a with plasmid pJM8 tel1<ura3, plasmid-borne tel1-HA(KD)
JMY303-1c Spore of JMY303 a mec1-21
JMY303-3a Spore of JMY303 a sml1<HIS3 tel1<ura3
JMY303-8a Spore of JMY303 a tel1<ura3
JMY303-8d Spore of JMY303 mec1-21 sml1<HIS3
JMY312 Cross of MD78 and JMY303-8a aya tel1<ura3yTEL1 sml1<HIS3ySML1
MEC1-HAyMEC1
JMY312-6d Spore derived from JMY312 sml<HIS3 tel1<ura3 MEC1-HA
JMY312-8c Spore derived from JMY312 sml<HIS3 tel1<ura3 MEC1-HA
JMY313 Cross of MD85 and JMY303-3a aya mec1-HA(KD)yMEC1 tel1<ura3yTEL1
sml1<HIS3ysml1<HIS3
JMY313-9a Spore derived from JMY313 mec1-HA(KD) sml1<HIS3 tel1<ura3
JMY314 Cross of RCY278-5b and MD85 aya mec1-HA(KD)yMEC1 rad5-535yRAD5
sml1<HIS3ySML1§
JMY314-3d Spore derived from JMY314 mec1-HA(KD) sml1<HIS3 rad5-535
JMY314-5a Spore derived from JMY314 a mec1-HA(KD) sml1<HIS3 RAD5
*Most of the strains in the study are isogenic (except for changes introduced by transformation) with W303a (a leu2-3,112 his3-11,15 ura3-1 ade2-1 trp1-1
rad5-535 can1-100). All genes that differ from those of the progenitor genotype are listed.
†Details of these constructions are in Materials and Methods.
‡This strain also contains an insertion of URA3 near the telomere of chromosome XVL (TELXVL<URA3; [24]).
§This diploid is heterozygous for the TELXVL<URA3 marker.
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transform JMY73 (an sml1 derivative of W303a) and, as de-
scribed above, in two steps we obtained a strain with an
HA-tagged version of MEC1 (MEC1-HA). This strain (MD78)
had wild-type sensitivity to hydroxyurea, as would be expected
if the HA-tagged Mec1p was fully functional.
A yeast strain with an HA-tagged version of Mec1p with mutant
substitutions in the kinase domain also was generated. The plasmid
pMD81 was treated with KpnI and a two-step transplacement was
performed with strain MD78 (MEC1-HA sml1::HIS3). The plasmid
pMD81 had a 1.2-kb fragment containing the kinase domain of
MEC1 with two mutant substitutions, D-to-A at position 2,224 and
N-to-K at position 2,229. This plasmid was generated by a series of
three PCR reactions. Primers A [59-GACACTATAGTGATCA-
CACTAGAGTCTAACTCAATGAG-39, MEC1 sequences up-
stream of the introduced mutations plus an introduced BclI site
(underlined)] and B [59-CTTTACCCGTCTGTATATCTAGTA-
ATATCTTTTCACAGTGCCTAGCACCTAGACCTAATAT-
ATGGCCAAC-39; MEC1 sequences with two introduced muta-
tions in kinase domain (underlined)] were used in one PCR, and
primers C [59-GTTGGCCATATATTAGGTCTAGGTGCTAG-
GCACTGTGAAAAGATATTACTAGATATACAGACGGG-
TAAAG-39, the complement of primer B with the introduced
mutations (underlined)] and D [59-TTCAGACAGGTGAT-
CACGTCTGTTGCCGAAAATGGTG-39, containing MEC1 se-
quences downstream of the introduced mutations plus an intro-
duced BclI site (underlined)] were used in a second PCR. The
products of these reactions then were used as templates for a third
reaction by using primers A and D. The net result of these
manipulations was a 1.2-kb fragment containing MEC1 sequences
with the mutant alterations near the middle of the fragment. This
fragment was treated with BclI and inserted into the BamHI site of
YIp5 to create pMD81.
Kinase AssaysyWestern Blots. To isolate protein for the kinase assays
and the Western blot, we grew strains containing HA-tagged Te1lp
or Mec1p to mid-log phase (OD600 5 0.5). The preparation of
protein extracts, immunoprecipitations, and kinase assays were
done as described for the Tor1p kinase (19). In brief, protein
extracts were prepared by sonication of oxalyticase-generated
spheroplasts (Enzogenetics, Corvallis, OR). To extracts containing
2 mg of total protein in lysis buffer (50 mM Hepes, pH 7.4y100 mM
KCly0.1 mM EDTAy0.2% Tween-20y1 mM DTTy20 mM b-
glycerophosphatey20 mM NaFy100 mM Na3VO4y1 mM PMSF), we
added 1 ml of HA.11 antibody (Babco, Richmond, CA) and
incubated the mixture on a rotator at 4° for 2 h. Protein A sepharose
CL-4B beads (45 ml; equilibrated in lysis buffer) were added and the
incubation continued for 2 h. The beads then were washed and
resuspended in 45 ml of kinase buffer (10 mM Hepes, pH 7.4y
50 mM NaCly10 mM MnCl2y1 mM DTT). Kinase reactions
contained 15 ml of washed beads, 11.5 ml of kinase buffer, 1.5 ml of
200 mM unlabeled ATP, 10 mCi of g32P-labeled ATP (4,500
Ciymmol; 1 Ci 5 37 GBq), and 1 ml of PHAS-I (1 mgyml;
Stratagene). The reactions were performed at 30° for 30 min. In
studies involving wortmannin, the beads with the immunoprecipi-
tated proteins were incubated for 30 min at room temperature with
wortmannin that was diluted in kinase buffer lacking DTT. Kinase
assays with the treated beads then were performed as described
above.
Western Blot Analysis. The relative levels of Tel1p-HA and
Mec1p-HA were examined by Western blots. The HA-tagged
proteins were immunoprecipitated from 8 mg of total protein as
described above. Washed beads (45 ml) containing the immu-
noprecipitated proteins were resuspended in SDSyPAGE load-
ing buffer, heated at 95° for 10 min, and then loaded onto a 5%
SDSyPAGE gel. After electrophoresis, the proteins were trans-
ferred onto a Hybond-C membrane (Amersham Pharmacia).
The membrane was preincubated with TBST buffer (20 mM Tris,
pH 7.8y150 mM NaCly0.1% Tween-20) containing 5% (volyvol)
powdered milk for 2 h at 4°. The HA.11 antibody was then added
(1:1,000 dilution) in fresh TBSTypowdered milk and the incu-
bation continued for 2 h at 4°. The membrane then was washed
three times with TBST and incubated with a 1:1,000 dilution (in
TBSTypowdered milk buffer) of the anti-mouse secondary
antibody-horseradish peroxidase conjugate (Amersham Phar-
macia) for 1 h at 4°. The blot then was washed three times in
TBST, developed with the enhanced chemiluminescence reagent
ECL (Amersham Pharmacia), and exposed to film.
Southern Analysis of Telomere Length. Details of this analysis have
been published previously (3). Yeast DNA was treated with PstI
and the resulting fragments were separated by gel electrophore-
sis. The fragments were transferred to Hybond N1 nylon
membranes and hybridized to a probe (derived from pYT14) that
contained telomeric DNA and a portion of the Y9 subtelomeric
repeat.
Sequence Analysis of Mec1–21. The MEC1 gene was sequenced
(using a set of 11 primer pairs spaced evenly through the gene)
in two strains (JMY303–2b and JMY303–6c; ref. 3) containing
the mec1–21 mutation (6, 8) and the isogenic wild-type strain
W303a. A single mutant substitution was detected, a G-to-A at
position 2,644 (G882S).
Results
Tel1p- and Mec1p-Dependent Phosphorylation of PHAS-I. To inves-
tigate whether Tel1p and Mec1p are protein kinases, we con-
structed strains in which the Tel1p or Mec1p protein was tagged
with an HA epitope. In the strain JMY48 (Table 1), the
HA-tagged TEL1 gene is on a high-copy plasmid. tel1 strains
with this plasmid had telomeres of nearly wild-type length,
indicating that the HA-tagged version of Tel1p was functional
(K. Ritchie and T.D.P., unpublished data). We used antibodies
directed against the HA tag to immunoprecipitate Tel1p (details
in Materials and Methods). The immunoprecipitated Tel1p effi-
ciently phosphorylated the protein substrate PHAS-I (Fig. 1a,
lane 1), a target of other members of the ATM-kinase family. No
kinase activity was detected when a mock immunoprecipitation
(no HA-specific antibody) was performed in extracts derived
from the same strain (Fig. 1a, lane 2). More importantly, no
phosphorylation of PHAS-I was observed when immunoprecipi-
tates were derived from a strain (JMY103) in which the plasmid-
borne HA-tagged TEL1 gene had four mutant substitutions
(G2611D, D2612A, N2616K, and D2631E) in the kinase domain
(Fig. 1a, lane 3). We have shown that these mutant substitutions
result in a short-telomere phenotype (2). Kinase activity also was
detectable when TEL1-HA was present as a single chromosomal
copy (KRY22; Fig. 1a, lane 4).
A comparable series of experiments also were performed with
HA-tagged Mec1p. When immunoprecipitates were prepared
from JMY312–8c (MEC1-HA tel1::ura3 sml1::HIS3) and used in
a kinase reaction, we observed phosphorylation of PHAS-I (Fig.
1b, lane 1). Because the immunoprecipitates are derived from a
strain with the tel1 mutation, this activity cannot represent
coimmunoprecipitated Tel1p kinase activity. Most of the kinase
activity (.90%) was lost when extracts were prepared from a
strain [JMY313–9a; mec1-HA(KD) tel1::ura3 sml1::HIS3] in
which the HA-tagged MEC1 gene contained two mutations in
conserved amino acids in the kinase domain (D2224A and
N2229K; Fig. 1b, lane 2). As described below, strains with these
mutations have the same phenotype as null mec1 mutants.
The kinase activity observed in immunoprecipitates contain-
ing HA-tagged Tel1p and Mec1p, and the loss of this activity in
strains with point mutations in the kinase domains of these
proteins, strongly argues that Tel1p and Mec1p are protein
kinases. To ensure that the loss of kinase activity observed in the






immunoprecipitates derived from the tel1-HA(KD) and mec1-
HA(KD) strains did not reflect unstable or poorly immunopre-
cipitable proteins, we examined the relative levels of the HA-
tagged wild-type and kinase-dead versions of Tel1p and Mec1p.
No significant differences were detectable (Fig. 1c).
Because the ATM protein kinase family members are sensitive
to the phosphatidylinositol-3 kinase-inhibitor wortmannin (16,
17, 19), we examined the sensitivity of the Tel1p and Mec1p
kinase activities to this drug. Both Tel1p and Mec1p were
sensitive, although Tel1p was less sensitive than Mec1p (Fig. 2).
The sensitivity of Tel1p was intermediate to that observed
previously for ATM and ATR, whereas the sensitivity of Mec1p
was roughly similar to that seen for ATM (17).
Target(s) of Tel1p Kinase in PHAS-I. The commercially available
PHAS-I substrate used in our experiments contained an N-
terminal 20-aa tag (MGSSHHHHHHSSGLVPRGSH) in addi-
tion to the 117 aa of the rat PHAS-I protein (26). Because this
tag contains a thrombin-cleavage site (after Arg-17), we deter-
mined whether the tag was necessary for phosphorylation and
whether there was a phosphorylation site within the tag. As
shown in Fig. 3a, if the intact PHAS-I is phosphorylated and then
cleaved by thrombin, most of the radioactivity is retained in the
120-aa proteolytic fragment, indicating that at least some of the
phosphorylation sites are not within the tag. As shown in Fig. 3b,
if the tagged PHAS-I protein is cleaved before phosphorylation,
it is a very poor substrate for the Tel1p kinase. These results
indicate that the 20-aa tag is required for PHAS-I to act as a good
substrate for Tel1p, but the tag is not a unique target site for the
kinase. One possibility is that the highly charged tag helps
PHAS-I associate with Tel1p. Alternatively, the tag might allow
PHAS-I to form a different tertiary or quaternary structure,
creating a better Tel1p substrate.
Fig. 1. Kinase activities of Tel1p and Mec1p. (a) Kinase activity of immuno-
precipitated HA-tagged Tel1p on PHAS-I. Products of a kinase reaction using
labeled ATP were analyzed by SDSyPAGE. Strains from which immunoprecipi-
tates were derived: lane 1, JMY48 (high-copy-number plasmid with TEL1-HA);
lane 2, mock immunoprecipitate (no anti-HA antibody) from JMY48; lane 3,
JMY103 [high-copy number plasmid with tel1-HA(KD)]; lane 4, KRY22
(TEL1-HA in single chromosomal copy); and lane 5, JMY303–2a (tel1 strain, no
epitope-tagged Tel1p). (b) Kinase activity of immunoprecipitated HA-tagged
Mec1p on PHAS-I. Strains from which immunoprecipitates were derived: lane
1, JMY312–8c (tel1 sml1::HIS3 MEC1-HA); lane 2, JMY313–9a [tel1 mec1-
HA(KD) sml1::HIS3]; and lane 3, mock immunoprecipitate (no HA-antibody)
from JMY312–8c. (c) Western analysis of HA-tagged Tel1p and Mec1p pro-
teins. Immunoprecipitated HA-tagged Tel1p or Mec1p were examined by
Western analysis using HA.11 antibody and a secondary antibody-horseradish
peroxidase conjugate. Lane 1, JMY48 (high-copy number plasmid with TEL1-
HA); lane 2, JMY103 [high-copy number plasmid with tel1-HA(KD)]; lane 3,
JMY312–8c (MEC1-HA); and lane 4, JMY313–9a [mec1-HA(KD)]. Wt, wild type;
kd, kinase dead.
Fig. 2. Wortmannin sensitivity of the Tel1p and Mec1p kinases. Immuno-
precipitates from strains with either TEL1-HA (JMY48) or MEC1-HA (JMY312–
8c) were treated with wortmannin (details in Materials and Methods) before
kinase reactions were performed. Activities are normalized to a value of 1 for
immunoprecipitates incubated in the absence of wortmannin. Tel1p and
Mec1p activities are represented by F and h, respectively. Error bars indicate
standard deviations (total of three experiments).
Fig. 3. Requirement of 20-aa ‘‘tag’’ (MGSSHHHHHHSSGLVPRGSH) for PHAS-I
to function as a substrate for the Tel1p kinase. (a) PHAS-I was phosphorylated
by an immunoprecipitate derived from a strain with TEL1-HA (JMY48); the
final two washes of the immunoprecipitate were done in the absence of PMSF.
A portion of the sample was treated with thrombin (Roche Molecular Bio-
chemicals) to remove the N-terminal 17 aa; both the untreated (lane 1) and
treated (lane 2) samples were examined by gel electrophoresis. (b) Kinase
reactions with immunoprecipitated Tel1p were done with two samples. One
sample (lane 1) contained untreated PHAS-I. The sample in lane 2 was treated
with thrombin before performing the kinase reaction. Thrombin was inacti-
vated by addition of PMSF.
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To map the phosphorylation sites within PHAS-I, we sent a
gel-purified Tel1p-phosphorylated sample of PHAS-I to the
Harvard Microchemistry Facility (Boston) for analysis. Tryptic
digest of these proteins were analyzed by microcapillary reverse-
phase HPLC nano electrospray tandem mass spectrometry on a
Finnigan LCQ quadrupole ion trap mass spectrometer. This
analysis detected phosphorylation of Ser-131 in the tagged
version of PHAS-I; the sequence of the peptide with the
phosphorylated serine is RAGGEES*QFEMDI (asterisk indi-
cates the phosphorylated serine). Because this serine is followed
by a glutamine, Tel1p recognizes serine in an SQ motif, as
observed for most of the other ATM kinase family members.
Several other points concerning the phosphorylation sites
recognized by Tel1p and Mec1p should be mentioned. First, our
analysis does not exclude the possibility of other targets in
PHAS-I in addition to Ser-131. For example, there are two other
SQ sites in PHAS-I in addition to Ser-131. Second, our analysis
does not exclude the possibility of Tel1p and Mec1p recognizing
other motifs, such as TQ, in other proteins.
Requirement of the Kinase Domains of Tel1p and Mec1p for in Vivo
Functions. In another study (2), we showed that strains with four
mutations in the kinase domain of TEL1 (G2611D, D2612A,
N2616K, and D2631E) had short telomeres. This conclusion was
confirmed for the HA-tagged version of TEL1 [tel1-HA(KD)]
(Fig. 4a, lanes 3 and 4). We also showed that the mec1–21 allele
resulted in slightly shortened telomeres, but strains with both the
mec1–21 and sml1 mutation had telomeres of wild-type length
(3); mec1–21 is a hypomorphic allele that is viable in SML1
strains (6, 8). Because (as described below) mec1-HA(KD) is
inviable unless SML1 is mutated, we monitored telomere length
in the double-mutant mec1-HA(KD) sml1. Telomeres were of
wild-type length in the double mutant (Fig. 4a, lane 7). Strains
with the genotype tel1 mec1-HA(KD) sml1 had telomeres that
were slightly shorter than those observed in the tel1 single-
mutant strains (Fig. 4a, lane 8), indicating that the mec1-HA(KD)
allele affects telomere length.
Null mec1 mutations result in lethality, although this lethality
can be suppressed by the sml1 (suppressor of mec1 lethality)
mutation (10). To determine whether the mec1-HA(KD) allele
resulted in lethality, we sporulated a diploid (JMY314) that was
heterozygous for mec1-HA(KD) and sml1::HIS3. Of 15 tetrads
examined, 5 had four viable spores, 3 had three viable spores, and
7 had two viable spores, which was the pattern of spore viability
expected for a synthetic lethal interaction between unlinked
mutations. Of the 43 viable spores in these tetrads, 13 were
MEC1 SML1, 17 were MEC1 sml1::HIS3, 13 were mec1-HA(KD)
sml1::HIS3, and none were mec1-HA(KD) SML1. We conclude
that the mec1-HA(KD) allele, like mec1 null alleles, results in
lethality, but this lethality can be suppressed by sml1.
The mec1–21 allele is synthetically senescent with tel1; this
senescent phenotype is likely to ref lect a defect in telomere
length regulation (3). We examined the growth of spore
colonies (derived from JMY313 and JMY314) of the mec1-
HA(KD) sml1 and tel1 mec1-HA(KD) sml1 genotypes. As
shown in Fig. 4b, the triple-mutant spores grew very poorly
even in the first subcloning. Subsequent subclonings exhibited
a senescent phenotype similar to that observed previously for
tel1 mec1–21 sml1 strains (3).
Strains with mec1 mutations are sensitive to a number of
DNA-damaging agents and drugs such as hydroxyurea that cause
S phase arrest (4–8). As shown in Fig. 4c, the mec1-HA(KD)
strain was sensitive to UV light, hydroxyurea, and the radiom-
imetic drug streptonigrin. The mec1-HA(KD) sml1 strain was
considerably more sensitive to UV and streptonigrin than were
the mec1–21 or the mec1–21 sml1 strains. Because the mutant
substitution in mec1–21 is located outside of the kinase domain
(G882S), the strain with this substitution is not necessarily
kinase-deficient. It is interesting to note that the presence of the
sml1 mutation partially rescues the sensitivity of the mec1–21
mutants to UV irradiation and streptonigrin. Zhao et al. (10)
found that the sml1 mutation did not rescue the damage
sensitivity in a mec1–1 strain. In summary, for several different
phenotypes, mec1-HA(KD) strains resemble strains with mec1-
null alleles, indicating that the kinase activity of Mec1p is
important for its biological functions.
Fig. 4. Phenotypes of strains with mutations in the kinase domains of Tel1p
and Mec1p. (a) Assay for telomere length. DNA was isolated from strains of
various genotypes and treated with PstI. The resulting fragments were sepa-
rated by gel electrophoresis and hybridized to a telomeric-specific probe as
described in Materials and Methods. The dispersed band near the bottom of
the gel represents the terminal-DNA fragments of chromosomes with Y9-
containing telomeres. The strain name and genotype (indicated in parenthe-
ses) in each lane are: lanes 1 and 5, W303a (wild-type); lane 2, JMY303–2a
(tel1); lanes 3 and 4, JMY103 [tel1 1 plasmid-borne TEL1-HA(KD)]; lane 6,
JMY73 (sml1); lane 7, JMY314–3d [mec1-HA(KD) sml1 rad5]; and lane 8,
JMY313–9a [mec1-HA(KD) sml1 tel1::ura3]. (b) Assay for growth. Spore colo-
nies derived from the diploids JMY313 and JMY314 were streaked onto plates
containing rich growth medium and incubated at 30o for 2 days. The two tel1
mec1-HA(KD) sml1 strains are JMY313–3a and JMY313–9a, and the two
mec1-HA(KD) sml1 strains are JMY314–3d and JMY314–5a. (c) Assay of re-
sponse to DNA-damaging agents. Serial dilutions of six strains were prepared
on four plates containing rich growth medium (yeast extractypeptoney
dextrose). One plate was untreated without any DNA-damaging agent; one
was treated for 10 sec with UV light derived from a germicidal lamp; one
contained 10 mM hydroxyurea (HU); and one contained 2 mgyml streptoni-
grin. The strains used in the study (row 1 at the tops of the plates) were: row
1, W303a; row 2, W1588–4c (identical to W303a except RAD5 instead of
rad5–535); row 3, JMY303–1c; row 4, JMY303–8d; row 5, JMY314–3d; and row
6, JMY314–5a (identical to JMY314–3d except RAD5). Cells were grown for 2
days at 30°C.







Our analyses show that Tel1p and Mec1p are protein kinases.
The sensitivity of their kinase activity to wortmannin and the
demonstration that Tel1p is capable of phosphorylating serine in
an SQ motif indicate that the kinase activities of Tel1p and
Mec1p are related to those of other ATM family members. In
addition, we found that mutant substitutions in the kinase
domains of Tel1p and Mec1p result in phenotypes similar to
those found for null tel1 and mec1 alleles, indicating that the
kinase activity is essential for the biological function of these
proteins.
An important extension of these studies is to determine the in
vivo protein targets of Tel1p and Mec1p and the mechanism by
which phosphorylation of these targets is necessary for telomere-
length regulation and checkpoint functions. Because Tel1p
functions in the same pathway of telomere-length regulation as
proteins of the MRX complex (Mre11pyRad50pyXrs2p; ref. 9),
these proteins are obvious target candidates. We have found that
Xrs2p is a target for in vitro phosphorylation of Tel1p (J.C.M.,
K. Trujillo, P. Sung, and T.D.P., unpublished data), but have not
observed Tel1p-dependent phosphorylation of Xrs2p in vivo (K.
Ritchie and T.D.P., unpublished data). Based on the Mec1p-
andyor Tel1p-dependent phosphorylation observed in vivo for
other checkpoint proteins (11), these proteins are obvious
targets for direct phosphorylation by Tel1p andyor Mec1p. By
using immunoprecipitates of epitope-tagged Mec1p, Paciotti et
al. (22) showed that Ddc2p undergoes Mec1p-dependent phos-
phorylation in vivo and in vitro. They also found, as we did, that
mutations in the kinase domain of MEC1 resulted in lethality
unless they were suppressed by the sml1 mutation.
As discussed in the Introduction, Tel1p and Mec1p have
partially overlapping functions in two different pathways: te-
lomere-length regulation and DNA repair. The most straight-
forward interpretation of this functional overlap is that it reflects
an overlap in the ability of these proteins to phosphorylate their
targets. For example, DNA damage-induced phosphorylation of
Rad53p is Mec1p-dependent, but an additional plasmid-borne
copy of TEL1 can restore phosphorylation of Rad53p in a mec1
strain (8). The Tel1p and Mec1p share very limited homology
outside of the C-terminal kinase domain. It is likely that the
target preferences of the two proteins are not based on differ-
ences in the kinase domains, but rather on differences in the
N-terminal regions where, presumably, the different targets are
tethered to Tel1p and Mec1p to stabilize interactions with the
kinase domain. Because Tel1p requires a highly charged 20-aa
tag to efficiently phosphorylate PHAS-I, it will be interesting to
determine whether other targets of Tel1p might have a highly
positively charged domain required for its interaction with
Tel1p.
The Mec1p-dependent phosphorylation of Rad53p (8) and
other protein targets is induced by DNA damage. It would be of
interest to determine whether the kinase activity of Mec1p is
elevated in strains treated with various DNA-damaging agents.
One common feature in the metabolism of telomeres and the
repair of DNA damage is that both mechanisms involve DNA
ends, directly or indirectly. Because of this consideration, and
because Tel1p and Mec1p share homology with DNA-PK, the
effect of DNA ends on the kinase activity of these proteins
should also be examined.
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